60 Degrees Pharmaceuticals Reaches Babesiosis Study Enrollment Milestone
WASHINGTON, July 29, 2026 60 Degrees Pharmaceuticals, Inc. announced that it has successfully enrolled the minimum 24 patients required...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
WASHINGTON, July 29, 2026 60 Degrees Pharmaceuticals, Inc. announced that it has successfully enrolled the minimum 24 patients required...
WASHINGTON, July 8, 2026 60 Degrees Pharmaceuticals announced that it has entered into an exclusive option agreement with the...
